Report cover image

Middle East Active Pharmaceutical Ingredient CDMO Market Size, Share & Trends Analysis Report By Product (Traditional API, HP-API, Biologics) By Synthesis (Synthetic, Biotech), By Drug, By Application, By Workflow, By Region, And Segment Forecasts, 2025 -

Publisher Grand View Research
Published Sep 29, 2025
Length 150 Pages
SKU # GV20471171

Description

Market Size & Trends

The Middle East active pharmaceutical ingredient CDMO market size was estimated at USD 7.23 billion in 2024 and is projected to reach USD 11.64 billion by 2033, growing at a CAGR of 5.58% from 2025 to 2033. The market is driven by the growing prevalence of chronic diseases, a focus on generic and biosimilar drugs, and significant technological advancements. Supportive government policies, investment in pharmaceutical infrastructure, and streamlined regulatory processes further stimulate domestic and international players to expand operations in the region.

In addition, the shifting preference of pharmaceutical companies toward outsourcing complex manufacturing processes rather than investing heavily in in-house capabilities is also one of the factors contributing to the market growth. Outsourcing these activities helps pharmaceutical companies to focus more resources on innovation, clinical research, and market expansion. These factors reduce financial risks, shorten development timelines, and allow for faster scalability, which is particularly valuable in a region where healthcare demand is rising rapidly. Furthermore, global players are showing increasing interest in entering the Middle Eastern market due to its strategic geographic location, which offers access to both developed and emerging economies, making it an attractive hub for pharmaceutical trade and distribution.

Furthermore, increasing government initiatives aimed at strengthening local drug manufacturing to ensure regional supply security are also one of the factors fueling the market growth. Several countries in the region are prioritizing domestic production capabilities to reduce dependence on imports and improve access to essential medicines. This has opened opportunities for CDMOs that can provide advanced technologies and regulatory expertise to support local firms. In parallel, a growing number of collaborations and joint ventures between multinational pharmaceutical companies and regional players are accelerating knowledge transfer and boosting overall manufacturing capacity.

Middle East Active Pharmaceutical Ingredient CDMO Market Report Segmentation

This report forecasts revenue growth at regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the Middle East active pharmaceutical ingredient CDMO market report based on product, synthesis, drug, application, workflow, and country:
  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Traditional Active Pharmaceutical Ingredient (Traditional API)
  • Highly Potent Active Pharmaceutical Ingredient (HP-API)
  • Biologics
  • Synthesis Outlook (Revenue, USD Million, 2021 - 2033)
  • Synthetic
  • Biotech
  • Drug Outlook (Revenue, USD Million, 2021 - 2033)
  • Innovative
  • Generics
  • Workflow Outlook (Revenue, USD Million, 2021 - 2033)
  • Clinical
  • Commercial
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Oncology
  • Hormonal
  • Glaucoma
  • Cardiovascular disease
  • Diabetes
  • Others
  • Country Outlook (Revenue, USD Million, 2021 - 2033)
  • Saudi Arabia
  • UAE
  • Kuwait
  • Oman
  • Qatar
Please note The report will be delivered in 2-3 business days upon order notification.

Table of Contents

150 Pages
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Value chain based analysis (Model 2)
1.7.3. Multivariate Analysis (Model 3)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Middle East Active Pharmaceutical Ingredient CDMO Market: Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.2.3. Market Opportunities
3.3. Technological Landscape
3.4. Pricing Model Analysis
3.5. Supply Chain Analysis
3.6. Market Analysis Tools
3.6.1. Porter’s Five Forces Analysis
3.6.2. PESTEL by SWOT Analysis
Chapter 4. Middle East Active Pharmaceutical Ingredient CDMO Market: Product Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Middle East Active Pharmaceutical Ingredient CDMO Market Product Movement Analysis
4.4. Traditional Active Pharmaceutical Ingredient (Traditional API)
4.4.1. Traditional Active Pharmaceutical Ingredient (Traditional API) Market Estimates and Forecasts, 2021 - 2033 (USD million)
4.5. Highly Potent Active Pharmaceutical Ingredient (HP-API)
4.5.1. Highly Potent Active Pharmaceutical Ingredient (HP-API) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. Biologics
4.6.1. Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Middle East Active Pharmaceutical Ingredient CDMO Market: Synthesis Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Middle East Active Pharmaceutical Ingredient CDMO Market: Synthesis Movement Analysis
5.3. Middle East Active Pharmaceutical Ingredient CDMO Market Size & Trend Analysis, by Synthesis, 2021 to 2033 (USD Million)
5.4. Synthetic
5.4.1. Synthetic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Biotech
5.5.1. Biotech Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Middle East Active Pharmaceutical Ingredient CDMO Market: Drug Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Middle East Active Pharmaceutical Ingredient CDMO Market Drug Movement Analysis
6.3. Middle East Active Pharmaceutical Ingredient CDMO Market Size & Trend Analysis, by Drug, 2021 to 2033 (USD Million)
6.4. Innovative
6.4.1. Innovative Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Generics
6.5.1. Generics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Middle East Active Pharmaceutical Ingredient CDMO Market: Application Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Middle East Active Pharmaceutical Ingredient CDMO Market Application Movement Analysis
7.3. Middle East Active Pharmaceutical Ingredient CDMO Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
7.4. Oncology
7.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Hormonal
7.5.1. Hormonal Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6. Glaucoma
7.6.1. Glaucoma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7. Cardiovascular disease
7.7.1. Cardiovascular disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8. Diabetes
7.8.1. Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.9. Others
7.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Middle East Active Pharmaceutical Ingredient CDMO Market: Workflow Estimates & Trend Analysis
8.1. Segment Dashboard
8.2. Middle East Active Pharmaceutical Ingredient CDMO Market: Workflow Movement Analysis
8.3. Middle East Active Pharmaceutical Ingredient CDMO Market Size & Trend Analysis, by Workflow, 2021 to 2033 (USD Million)
8.4. Clinical
8.4.1. Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5. Commercial
8.5.1. Commercial Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 9. Middle East Active Pharmaceutical Ingredient CDMO Market: Country Estimates & Trend Analysis
9.1. Regional Market Dashboard
9.2. Regional Market Snapshot
9.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
9.4. Saudi Arabia
9.4.1. Key Country Dynamics
9.4.2. Competitive Scenario
9.4.3. Regulatory Framework
9.4.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.5. UAE
9.5.1. Key Country Dynamics
9.5.2. Competitive Scenario
9.5.3. Regulatory Framework
9.5.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.6. Kuwait
9.6.1. Key Country Dynamics
9.6.2. Competitive Scenario
9.6.3. Regulatory Framework
9.6.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.7. Oman
9.7.1. Key Country Dynamics
9.7.2. Competitive Scenario
9.7.3. Regulatory Framework
9.7.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.8. Qatar
9.8.1. Key Country Dynamics
9.8.2. Competitive Scenario
9.8.3. Regulatory Framework
9.8.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 10. Competitive Landscape
10.1. Company Categorization
10.1.1. Market Leaders
10.1.2. Emerging Players
10.2. Company Market Share Analysis, 2024
10.3. Company Profiles
10.3.1. Cambrex Corporation
10.3.1.1. Company Overview
10.3.1.2. Financial Performance
10.3.1.3. Product/Service Benchmarking
10.3.1.4. Strategic Initiatives
10.3.2. Recipharm AB
10.3.2.1. Company Overview
10.3.2.2. Financial Performance
10.3.2.3. Product/Service Benchmarking
10.3.2.4. Strategic Initiatives
10.3.3. Thermo Fisher Scientific Inc.
10.3.3.1. Company Overview
10.3.3.2. Financial Performance
10.3.3.3. Product/Service Benchmarking
10.3.3.4. Strategic Initiatives
10.3.4. CordenPharma International
10.3.4.1. Company Overview
10.3.4.2. Financial Performance
10.3.4.3. Product/Service Benchmarking
10.3.4.4. Strategic Initiatives
10.3.5. Samsung Biologics
10.3.5.1. Company Overview
10.3.5.2. Financial Performance
10.3.5.3. Product/Service Benchmarking
10.3.5.4. Strategic Initiatives
10.3.6. Lonza
10.3.6.1. Company Overview
10.3.6.2. Financial Performance
10.3.6.3. Product/Service Benchmarking
10.3.6.4. Strategic Initiatives
10.3.7. Catalent, Inc.
10.3.7.1. Company Overview
10.3.7.2. Financial Performance
10.3.7.3. Product/Service Benchmarking
10.3.7.4. Strategic Initiatives
10.3.8. Siegfried Holding AG
10.3.8.1. Company Overview
10.3.8.2. Financial Performance
10.3.8.3. Product/Service Benchmarking
10.3.8.4. Strategic Initiatives
10.3.9. Piramal Pharma Solutions
10.3.9.1. Company Overview
10.3.9.2. Financial Performance
10.3.9.3. Product/Service Benchmarking
10.3.9.4. Strategic Initiatives
10.3.10. Boehringer Ingelheim International GmbH
10.3.10.1. Company Overview
10.3.10.2. Financial Performance
10.3.10.3. Product/Service Benchmarking
10.3.10.4. Strategic Initiatives

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us